2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5899 Spatially restricted CAR T-cell inflammatory niches disrupt granulopoiesis and contribute to hematotoxicity

David Manuel Cordas Dos Santos, MD, Yao Yu Yeo, PhD2, Kane Foster, PhD3, Daniel Heilpern-Mallory4, Sophia Schroeder5, Maria-Theresa Silverio6, Jacqueline Perry, MPH7, Quentin Berry8, Hope Wei9, Shonali Midha, MD10, Gaddy Getz, PhD11, Omar Nadeem, MD12, Yoshinobu Konishi, MD, PhD13, Irene M Ghobrial, MD14
1 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, The Broad Institute of Harvard and MIT, Cambridge, United States
2 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, The Broad Institute of Harvard and MIT, Cambridge, United States
3 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, The Broad Institute of Harvard and MIT, Cambridge, United States
4 Dana-Farber Cancer Institute, Boston, United States, The Broad Institute of Harvard and MIT, Cambridge, United States
5 Dana-Farber Cancer Institute, Boston, United States
6 Dana-Farber Cancer Institute, Boston, United States
7 Dana-Farber Cancer Institute, Boston, United States
8 Dana-Farber Cancer Institute, Boston, United States
9 Dana-Farber Cancer Institute, Boston, United States
10 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
11 Harvard Medical School, Boston, United States, Massachusetts General Hospital, Boston, United States, The Broad Institute of Harvard and MIT, Cambridge, United States
12 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
13 Kyoto University Hospital, Kyoto, Japan
14 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, The Broad Institute of Harvard and MIT, Cambridge, United States

INTRODUCTION

Immune effector cell–associated hematotoxicity (ICAHT) is a frequent complication of CAR T-cell therapy and can cause prolonged neutropenia and life-threatening infections. Although systemic inflammatory and clinical risk factors have been described, the tissue-level mechanisms impairing hematopoietic recovery remain poorly understood. We hypothesized that BCMA-directed CAR T cells establish spatially restricted inflammatory niches within the bone marrow that disrupt granulopoiesis and contribute to hematotoxicity across the multiple myeloma disease spectrum.

 

METHODS

We performed Xenium spatial transcriptomics on paired pretreatment and day-30 whole-slide bone marrow biopsies from 10 patients with high-risk smoldering multiple myeloma (HR-SMM) receiving cilta-cel. A 5,000-gene panel supplemented with custom cilta-cel CAR-vector probes resolved approximately 1.2 million cells across 17 hematopoietic, immune, tumor, and stromal phenotypes. We developed a distance- and density-weighted CAR-T spatial score to compare cellular composition, transcriptional programs, and ligand–receptor interactions between CAR T cell–proximal and –distal regions, using endogenous CAR-negative T cells as spatial controls. Spatial features were quantified in relation to ICAHT, neutropenia severity, and peripheral blood and bone marrow CAR T-cell abundance. Key findings were validated by spatial proteomics across longitudinal cohorts spanning early-stage and relapsed/refractory multiple myeloma, including 17 patients with high-risk smoldering disease and 80 patients treated with cilta-cel or ide-cel.

 

RESULTS

All patients in the spatial transcriptomic cohort achieved measurable residual disease negativity by day 30, allowing evaluation of treatment-associated toxicity and microenvironmental remodeling in the context of a uniform early antimyeloma response. Plasma cells decreased from 28.0% to 0.5% and B cells from 2.0% to 0.3%, whereas macrophage and erythroid-lineage populations increased. These compositional changes were accompanied by broad induction of inflammatory, interferon-responsive, and immune-activation programs.

Custom probes targeting the cilta-cel CAR vector showed a marked increase in post-treatment signal, colocalized with T-cell lineage transcripts, and enabled direct identification of CAR-expressing T cells in situ. CAR T cells localized within distinct inflammatory niches enriched for macrophages and CD4 T cells that also exhibit elevated inflammatory interferon-responsive signatures. Additionally, macrophage–macrophage and macrophage–T-cell distances were reduced after treatment, whereas analogous spatial associations were not observed around endogenous CAR-negative T cells at baseline or after infusion. Chemokine ligand-receptor interaction analysis further revealed a spatial gradient, with minimal signaling at baseline, increased signaling in post-treatment CAR T cell–distal regions, and maximal signaling in CAR T cell–proximal regions. The dominant inferred interaction involved CXCL9–CXCR3 signaling among macrophages, CAR T cells, and endogenous CD4 T cells, with additional contributions from CXCL10–CXCR3 and CXCL16–CXCR6.

CAR T cell–proximal regions showed depletion of granulocytic precursors, enrichment of mature myeloid cells and neutrophils, and suppression of granulocytic differentiation programs. This pattern was absent around endogenous CAR-negative T cells. Of note, this spatial disruption of granulopoiesis was associated with both ICAHT severity and CTCAE neutropenia grade. Patients with more severe hematotoxicity demonstrated stronger CAR T cell–associated enrichment of macrophages, CD4 and CD8 T cells, increased inflammatory and interferon-responsive signaling, and more pronounced depletion of granulocytic precursor populations. Spatial proteomic validation across early-stage and relapsed/refractory cohorts confirmed the association between localized inflammatory remodeling and hematotoxicity across disease stages and CAR T-cell products.

CONCLUSIONS

By directly detecting CAR-expressing T cells in human bone marrow using CAR-vector–specific spatial probes, we provide in situ evidence that BCMA-directed CAR T cells establish localized inflammatory niches that disrupt granulopoiesis. These findings establish spatially restricted marrow inflammation surrounding CAR T-cells as a distinct mechanism contributing to hematotoxicity across the multiple myeloma disease spectrum.

David Manuel Cordas Dos Santos, MD: Regeneron - Research Funding